Michael Hunkapiller, Ph.D. | CEO & President
Michael Hunkapiller became President & CEO of Pacific Biosciences in 2012. He has served on the Board since 2005. Dr. Hunkapiller spent over 30 years of his career helping build Applied Biosystems (“ABI,” now part of Thermo Fisher Scientific Inc.) into a market leader in the life sciences industry. From 1995 to 2004, he served as ABI’s President and General Manager. In 2004, he joined Alloy Ventures as a General Partner, and in 2005 led Alloy’s investment in PacBio.
During his term at ABI, Dr. Hunkapiller developed the R&D strategies and alliances that elevated ABI to be the foremost supplier of molecular-biology reagents and instrumentation in academic and industrial laboratories. He was also a founder of ABI’s sister company, Celera Genomics, and Senior Vice President of Applera Corporation (Celera’s parent company).
Prior to joining ABI, Dr. Hunkapiller was a senior research fellow in the Division of Biology at the California Institute of Technology. He received a B.S. in Chemistry from Oklahoma Baptist University and a Ph.D. in Chemical Biology from the Division of Chemistry and Chemical Engineering at Caltech. He has authored more than 100 scientific publications, is an inventor on more than two-dozen patents, and has served on the editorial boards of several scientific journals. He has received several awards for his contributions to life science research.
Susan K. Barnes | Executive Vice President and Chief Financial Officer
Susan K. Barnes joined PacBio in February 2010 with nearly 30 years’ experience in senior financial management. From 1997 to 2005, she was Senior Vice President, Finance and Chief Financial Officer of Intuitive Surgical, Inc. Ms. Barnes started at Intuitive Surgical as its first full-time finance person during the company’s early development stages, and retired when it was a public company with a market capitalization of more than $3 billion and positive cash flow of more than $50 million a year. From 1994 to 1996, Ms. Barnes was Managing Director of the Private Equity Group at Jefferies & Company. From 1991 to 1994, she was Chief Financial Officer and Managing Director of Richard C. Blum and Associates, a merchant banking company with more than $500 million in funds under management. From 1985 to 1991, she served as Vice President and Chief Financial Officer of NeXT Computer, Inc., a company she helped start with Steve Jobs after serving as Controller of the Macintosh Division at Apple Computer from 1981-1985.
In addition to her role at Pacific Biosciences, Ms. Barnes sits on the Board of Trustees for The Nueva School in Hillsborough, CA.
Ms. Barnes received an A.B. from Bryn Mawr College and an M.B.A from the Wharton School, University of Pennsylvania.
Jonas Korlach, Ph.D. | Chief Scientific Officer
Jonas Korlach was appointed Chief Scientific Officer of Pacific Biosciences in July 2012. He was previously a Scientific Fellow, supporting commercial development of the PacBio RS II system and performing research aimed at developing new applications for SMRT technologies. He co-invented the SMRT technology with Stephen Turner, Ph.D., Pacific Biosciences Founder and Chief Technology Officer, when the two were graduate students at Cornell University. Dr. Korlach joined Pacific Biosciences as the company’s eighth employee in 2004. Previously, he was a Postdoctoral Researcher at Cornell University.
Dr. Korlach is the recipient of multiple grants, an inventor on 70 issued U.S. patents and 61 international patents, and an author of over 70 scientific studies on the principles and applications of SMRT technology, including publications in Nature, Science, and PNAS. In 2013, Dr. Korlach was honored by the Obama White House as an Immigrant Innovator “Champion of Change.” He received both his Ph.D. and his M.S. degrees in Biochemistry, Molecular and Cell Biology from Cornell, and received M.S. and B.A. degrees in Biological Sciences from Humboldt University in Berlin, Germany.
Chris Seipert | Vice President of Sales & Support
Chris Seipert joined PacBio in 2009 and serves as Vice President of Sales and Support for the Americas and EMEA. In his early years at PacBio, Mr. Seipert held management roles in Instrument Engineering and Manufacturing. He led the development of the instrument manufacturing team and supply chain to support the launch of PacBio’s first commercial sequencing system, the PacBio RS. With his skill for optimizing systems and processes, he expanded his responsibilities to include directing the Field Service and Support teams. Under his leadership, PacBio developed a best-in-class customer support organization. In recent years, Mr. Seipert led a companywide initiative that improved the reliability of the Sequel System. In early 2019, Mr. Seipert assumed responsibility for the Sales organization and led the successful commercial launch of the Sequel II System in the Americas and EMEA. He is passionate about the customer experience, as evidenced by the product reliability improvements and customer-centric commercial teams that he has championed during his time at PacBio.
Prior to joining PacBio, Mr. Seipert held engineering and management roles at KLA-Tencor who provide process control and yield management systems for the semiconductor industry. He holds a Bachelor of Science in Physics and a Master of Science in Engineering from San Jose State University.
Stephen Turner, Ph.D. | Chief Technical Officer
Dr. Turner founded Pacific Biosciences (formerly Nanofluidics) and in 2004 secured its Series A funding. He was awarded a Ph.D. in Physics by Cornell University in 2000, where he worked with Prof. Harold Craighead to study the behavior of biomolecules in nano-fabricated structures. He was a member of the project team at Cornell which developed the technology now employed by Pacific Biosciences and was co-author of the cover story in Science magazine (January 31, 2003) that introduced the technology to the scientific community. Dr. Turner’s undergraduate work was at the University of Wisconsin, Madison, where he received a Bachelor of Science in Applied Mathematics, Electrical Engineering and Physics. He is the author of over 50 scientific papers in fields ranging from DNA sequencing technology and biophysics to genomics and epigenomics. He is listed as the inventor on over 50 U.S. patents and numerous published patent applications. Dr. Turner was recipient of the MIT Technology Review “TR100” Award in 2003 and the University of Wisconsin Madison Distinguished Young Alumnus Award in 2008.
Denis Zaccarin, Ph.D. | Senior Vice President, Research & Development
Dr. Zaccarin joined PacBio in 2004 as Director of Engineering. He initially led the development of the research tools used by Pacific Biosciences to generate the first sequencing results. He was promoted VP of Engineering in 2010 and managed the development of the first commercial platform RSII. Since 2012 he has been occupying the role of VP Semiconductor Integration Devices, leading the development of the consumables used in the Sequel and Sequel II platforms. Prior to joining Pacific Biosciences, Dr Zaccarin held various engineering and leadership roles at Bell-Northern Research, Nortel, Cambrian Systems, ONI systems and Ciena. Dr. Zaccarin was promoted to Senior Vice President, Research and Development, effective April 1, 2020. Dr. Zaccarin holds B.Sc.E (1987) and M.Sc.E (1989) from Laval University and a Ph.D in Electrical Engineering, Optics (1993) from University of Ottawa.